Clinical trial
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in…
NCT00191984 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191984 |
|---|---|
| Title | A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer |
| Official title | Open Multicenter Phase II Study in Second-Line Metastatic Colorectal Cancer Patients: Combination of ALIMTA and Irinotecan Administered Every Two-Weeks |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, irinotecan |
| Enrollment | 46 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 5, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: